Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Analysts at Leerink Swann cut their Q3 2019 EPS estimates for Amicus Therapeutics in a research report issued on Monday, September 10th, Zacks Investment Research reports. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($0.21) per share for the quarter, down from their previous forecast of ($0.19). Leerink Swann also issued estimates for Amicus Therapeutics’ Q4 2019 earnings at ($0.21) EPS, FY2019 earnings at ($0.87) EPS and FY2020 earnings at ($0.64) EPS.
A number of other equities analysts also recently issued reports on FOLD. BidaskClub downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, June 8th. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Tuesday, July 10th. ValuEngine downgraded Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 19th. Finally, Chardan Capital downgraded Amicus Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $18.00 to $15.00 in a research note on Friday, August 17th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Amicus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $19.33.
Shares of FOLD stock traded up $0.25 during trading hours on Wednesday, reaching $13.44. 4,279,719 shares of the company’s stock were exchanged, compared to its average volume of 2,630,857. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -4.60 and a beta of 1.33. Amicus Therapeutics has a 1 year low of $11.57 and a 1 year high of $17.62. The company has a current ratio of 10.88, a quick ratio of 10.73 and a debt-to-equity ratio of 0.30.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.33). The business had revenue of $21.31 million during the quarter, compared to the consensus estimate of $18.92 million. Amicus Therapeutics had a negative return on equity of 53.45% and a negative net margin of 460.04%.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Massachusetts Financial Services Co. MA grew its holdings in shares of Amicus Therapeutics by 1.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 776,230 shares of the biopharmaceutical company’s stock worth $12,125,000 after acquiring an additional 10,809 shares during the period. Ardsley Advisory Partners grew its holdings in Amicus Therapeutics by 16.1% during the 2nd quarter. Ardsley Advisory Partners now owns 505,000 shares of the biopharmaceutical company’s stock valued at $7,888,000 after buying an additional 70,000 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Amicus Therapeutics by 7.2% during the 1st quarter. Principal Financial Group Inc. now owns 134,648 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 9,027 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Amicus Therapeutics during the 2nd quarter valued at $11,048,000. Finally, Morgan Stanley grew its holdings in Amicus Therapeutics by 519.6% during the 2nd quarter. Morgan Stanley now owns 4,968,627 shares of the biopharmaceutical company’s stock valued at $77,610,000 after buying an additional 4,166,756 shares during the last quarter.
In other news, major shareholder Perceptive Advisors Llc purchased 20,000 shares of the stock in a transaction that occurred on Monday, September 24th. The shares were acquired at an average price of $12.45 per share, for a total transaction of $249,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 500,000 shares of the stock in a transaction that occurred on Wednesday, September 12th. The stock was purchased at an average price of $12.00 per share, for a total transaction of $6,000,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 620,000 shares of company stock worth $7,505,000. Insiders own 2.90% of the company’s stock.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
See Also: Fundamental Analysis and Choosing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.